Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy

DOI: 10.1371/journal.pone.0152840

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text